Media & Resources

NEW YORK, May 30, 2012—The International AIDS Vaccine Initiative (IAVI) is pleased to announce the appointment of Louis Schwartz as Chief Financial Officer. In this role, Schwartz will oversee the financial operations of the organization, working closely with IAVI’s Senior Management Team and Board of Directors. He will also lead IAVI’s Finance & Administration team,…

A Phase I clinical trial comparing a daily regimen of antiretroviral pre-exposure prophylaxis (PrEP) with an intermittent regimen found that rates of adherence to intermittent dosing regimens were lower than adherence to daily dosing.  The study is the first ever to report data on intermittent antiretroviral PrEP use in humans.  The results from this trial…

New Data Illustrates Potential Impact of AIDS Vaccine May 18, 2012—Today, on World AIDS Vaccine Day, we are reminded that AIDS continues to devastate the lives of millions of people across the globe, orphaning children, ravaging communities and disrupting economies. The effort to end the AIDS pandemic requires truly global commitment, and we must continuously…

NEW YORK, NY, GAITHERSBURG, MD, and ATHENS, GA, May 9, 2012 – The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, Inc. (GMI), and Glycosensors and Diagnostics, LLC (G&D) today announced a collaboration to develop an AIDS vaccine using novel compounds that mimic carbohydrates, called glycomimetics.  The project will be funded by IAVI’s Innovation Fund, a program…

IAVI extends its sincerest congratulations to Jose Esparza upon being awarded the Congressional Medal of Merit for his lifelong contributions to global health and efforts to end the AIDS pandemic. Jose’s unwavering dedication to such efforts and his steady leadership in the arena of AIDS vaccine development has been instrumental to advancing the field and…

NEW YORK, NY—APRIL 9, 2012—The International AIDS Vaccine Initiative (IAVI) announces the appointment to its Board of Directors of Dr. Adel A.F. Mahmoud, professor at Princeton University, former President of Merck Vaccines and former Chairman of Medicine at Case Western Reserve University. He joins a diverse group of 12 directors from ten countries with backgrounds…

NEW YORK and HASSELT, BELGIUM, March 19, 2012—The International AIDS Vaccine Initiative (IAVI) and Complix NV today announced a new collaboration to apply a novel approach to understanding the structure of a critical piece of the HIV Envelope protein complex. This collaboration will help advance the development of HIV vaccine candidates that can generate broadly…

The International AIDS Vaccine Initiative (IAVI) awards $875,000 in grants to two researchers identified through NineSigma’s Open Innovation process CLEVELAND, Ohio, February 21, 2012 – A collaboration between NineSigma and the International AIDS Vaccine Initiative (IAVI) is helping to advance HIV vaccine research by identifying new approaches to the design of a potential vaccine. A…